Prudential Financial Inc. Invests $39,000 in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL)

Prudential Financial Inc. bought a new stake in shares of Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) during the 4th quarter, according to its most recent filing with the SEC. The fund bought 12,840 shares of the company’s stock, valued at approximately $39,000.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in ZNTL. Sei Investments Co. bought a new position in Zentalis Pharmaceuticals during the fourth quarter worth about $107,000. Virtu Financial LLC bought a new stake in Zentalis Pharmaceuticals in the fourth quarter valued at $76,000. Thrivent Financial for Lutherans raised its stake in Zentalis Pharmaceuticals by 155.9% during the fourth quarter. Thrivent Financial for Lutherans now owns 70,641 shares of the company’s stock worth $214,000 after acquiring an additional 43,036 shares in the last quarter. Primecap Management Co. CA lifted its holdings in shares of Zentalis Pharmaceuticals by 1.5% during the fourth quarter. Primecap Management Co. CA now owns 1,520,630 shares of the company’s stock valued at $4,608,000 after acquiring an additional 22,600 shares during the period. Finally, Connor Clark & Lunn Investment Management Ltd. boosted its stake in shares of Zentalis Pharmaceuticals by 50.6% in the 4th quarter. Connor Clark & Lunn Investment Management Ltd. now owns 345,039 shares of the company’s stock valued at $1,045,000 after purchasing an additional 115,901 shares in the last quarter.

Zentalis Pharmaceuticals Trading Up 8.8 %

Shares of NASDAQ:ZNTL opened at $1.23 on Friday. The stock has a market capitalization of $88.33 million, a P/E ratio of -0.49 and a beta of 1.80. Zentalis Pharmaceuticals, Inc. has a 1-year low of $1.01 and a 1-year high of $14.07. The business has a 50-day moving average price of $1.84 and a two-hundred day moving average price of $2.64.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last announced its quarterly earnings data on Wednesday, March 26th. The company reported ($0.66) earnings per share for the quarter, beating the consensus estimate of ($0.75) by $0.09. The business had revenue of $26.90 million during the quarter. As a group, equities analysts predict that Zentalis Pharmaceuticals, Inc. will post -2.42 EPS for the current year.

Insider Transactions at Zentalis Pharmaceuticals

In other news, insider Ingmar Bruns purchased 20,000 shares of the business’s stock in a transaction that occurred on Thursday, February 6th. The shares were acquired at an average cost of $2.28 per share, for a total transaction of $45,600.00. Following the transaction, the insider now directly owns 36,629 shares of the company’s stock, valued at approximately $83,514.12. The trade was a 120.27 % increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at this link. Also, Director Jan Skvarka acquired 60,000 shares of Zentalis Pharmaceuticals stock in a transaction that occurred on Friday, January 31st. The shares were purchased at an average cost of $1.72 per share, for a total transaction of $103,200.00. Following the purchase, the director now directly owns 149,551 shares in the company, valued at $257,227.72. The trade was a 67.00 % increase in their ownership of the stock. The disclosure for this purchase can be found here. 3.60% of the stock is owned by corporate insiders.

Analyst Ratings Changes

A number of brokerages recently issued reports on ZNTL. Wedbush reiterated a “neutral” rating and set a $4.00 target price on shares of Zentalis Pharmaceuticals in a research report on Friday, March 28th. UBS Group cut their price objective on Zentalis Pharmaceuticals from $5.00 to $2.20 and set a “neutral” rating for the company in a research report on Tuesday, January 28th. Wells Fargo & Company lowered their target price on Zentalis Pharmaceuticals from $8.00 to $6.00 and set an “equal weight” rating for the company in a research note on Thursday, January 30th. Finally, HC Wainwright reiterated a “buy” rating and set a $10.00 price target on shares of Zentalis Pharmaceuticals in a research report on Thursday, March 27th. Five investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $8.24.

Zentalis Pharmaceuticals Company Profile

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.